根据研究生院《关于开展2023年度“圣和研究生创新成果奖”评选工作的通知》规定，经个人申报、学院审核及专家评审等程序，评定何思瑜等8名同学获得国际医药商学院2023年度“圣和研究生创新成果奖”，现将获奖名单予以公示。公示时间自2023年11月15日至20日，公示期内对获选名单有异议者，可向学院书面提出意见。联系人：刘老师，联系电话：86185036。
中国药科大学国际医药商学院
2023年11月15日
序号 | 姓名 | 学号 | 学科专业 | 发表论文题目 | 发表期刊 | 获奖等级 | 奖金金额 |
1 | 何思瑜 | 3320041598 | 管理药学 | Psychometric Comparison of EQ-5D-Y, CHU-9D, and PedsQL 4.0 in Chinese Children and Adolescents With Functional Dyspepsia: A Multicenter Study | value in health | 二等奖 | 2000 |
2 | 谷阳 | 3222041131 | 社会与管理药学 | Does China’s centralize volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? | Frontiers in Pharmacology | 三等奖 | 1000 |
3 | 邵泰航 | 3221041150 | 药物经济学 | Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing | BioDrugs | 三等奖 | 1000 |
4 | 代展菁 | 3121040194 | 药物经济学 | Whether and How Disutilities of Adverse Events were Used in the Economic Evaluation of Drug Therapy for Cancer Treatment | PHARMACOECONOMICS | 三等奖 | 1000 |
5 | 陈亮江 | 3320041593 | 管理药学 | Development and validation of pharmaceutical care barriers scale in Chinese hospitals: a cross-sectional survey | Frontiers in Pharmacology | 三等奖 | 1000 |
6 | 梁乐怡 | 3321041252 | 管理药学 | Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China | BMC Public health | 三等奖 | 1000 |
7 | 那昕 | 3221041125 | 社会与管理药学 | Effects of Basic Medical Insurance Consolidation on Subjective Well-being of Residents in China: Empirical Evidence from a Quasi-experiment | Frontiers in Public Health | 三等奖 | 1000 |
8 | 蒙文鑫 | 3322041279 |
| Female perspective: the burden of Alzheimer's disease and other dementias in China from 1990 to 2019 and prediction of their prevalence up to 2044 | Frontiers in Public Health | 三等奖 | 1000 |
